NantBioscience Overview

  • Founded
  • 2013
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $205M
Latest Deal Amount
  • Investors
  • 1

NantBioscience General Information


Developer of molecularly targeted drugs designed to treat cancer, infectious diseases, and inflammatory diseases. The company's drugs are targeted at tumor signaling pathways in patients with specific genetic mutations, enabling patients to have access to new therapeutic alternatives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 9920 Jefferson Boulevard
  • Culver City, CA 90232
  • United States
+1 (310) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NantBioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 01-Jun-2015 $205M 00000 00000 Completed Startup
To view NantBioscience’s complete valuation and funding history, request access »

NantBioscience Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.0 000 000 00 000 00.000
To view NantBioscience’s complete cap table history, request access »

NantBioscience Executive Team (2)

Name Title Board Seat Contact Info
Patrick Soon-Shiong MD Chief Executive Officer
Shahrooz Rabizadeh Ph.D Chief Scientific Officer
To view NantBioscience’s complete executive team members history, request access »

NantBioscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Celgene Corporation Minority 000 0000 000000 0
To view NantBioscience’s complete investors history, request access »